IP Verse

Maiwald Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Maiwald Gmbh

Patent Number:
EP3263106
Title:
Method For Suppressing Bitterness Of Quinoline Derivative
Applicant:
EISAI R&D MANAGEMENT CO., LTD.
Opposition Date:
Jul 23, 2024
Patent Number:
EP3334747
Title:
Charged Depth Filtration Of Antigen-Binding Proteins
Applicant:
AMGEN INC.
Opposition Date:
Jun 27, 2024
Patent Number:
EP3634463
Title:
Improved Protocol For Treatment Of Lupus Nephritis
Applicant:
AURINIA PHARMACEUTICALS INC.
Opposition Date:
Jun 26, 2024
Patent Number:
EP4114465
Title:
Anti-Ifnar1 Dosing Regime For Subcutaneous Injection
Applicant:
ASTRAZENECA AB
Opposition Date:
May 29, 2024
Patent Number:
EP3756730
Title:
Patient Motion Tracking System Configured For Automatic Roi Generation
Applicant:
VISION RT LIMITED
Opposition Date:
Apr 19, 2024
Patent Number:
EP3864053
Title:
Treatment Of Rms By Switching Therapy
Applicant:
NOVARTIS AG
Opposition Date:
Apr 5, 2024
Patent Number:
EP3769781
Title:
Stable Anti-Ifnar1 Formulation
Applicant:
ASTRAZENECA AB
Opposition Date:
Jan 18, 2024
Patent Number:
EP3393510
Title:
Zika Virus Vaccine
Applicant:
VALNEVA AUSTRIA GMBH
Opposition Date:
Nov 21, 2023
Patent Number:
EP3517539
Title:
Substituted Dimeric Quinazoline Derivative, Its Preparation And Its Use In Pharmaceutical Compositions For The Treatment Of Type I And Ii Diabetes
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Opposition Date:
Sep 13, 2023
Patent Number:
EP3199952
Title:
Method For Measuring Reactivity Of Fviii
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Aug 2, 2023

Competitors of Maiwald Gmbh

F. HOFFMANN-LA ROCHE AG

AMGEN INC.

GENENTECH, INC.

Want to track Maiwald Gmbh?

Feel free to send us a message here and we will get back to you